ArticleSurgery today2026
Preoperative plasma anti-DNAJB8 autoantibody and postoperative outcomes in breast cancer: an exploratory analysis.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeWe evaluated the clinical significance of plasma autoantibodies against cancer stem cell-associated antigens in breast cancer, with diagnostic performance as the primary endpoint and clinicopathological and prognostic relevance as secondary endpoints.
methodsIn this single-center observational study, autoantibodies against SOX2, survivin, and DNAJB8 were measured using ELISA. The diagnostic performance of anti-DNAJB8 autoantibodies was evaluated in 292 patients with breast cancer and 24 benign controls. Clinicopathological and postoperative analyses were exploratory in a preoperative cohort (175 patients).
resultsOnly DNAJB8 showed a distinct high-titer subset in the breast cancer group. The primary endpoint was not met, as plasma anti-DNAJB8 autoantibodies showed a non-significant diagnostic performance (AUC, 0.602; 95% CI, 0.488-0.715; P = 0.080). In the preoperative cohort, with six deaths and 11 recurrences, anti-DNAJB8 autoantibody positivity was associated with a worse overall and recurrence-free survival in age-adjusted analyses using Firth's penalized likelihood Cox regression (overall survival: hazard ratio, 10.607; 95% CI, 2.280-61.840; P = 0.003; recurrence-free survival: hazard ratio, 4.329; 95% CI, 1.247-13.082; P = 0.023).
conclusionThe primary diagnostic endpoint was not achieved for plasma anti-DNAJB8 autoantibodies. However, anti-DNAJB8 autoantibody positivity was associated with poorer postoperative outcomes, suggesting a hypothesis-generating prognostic relevance.
Indexed as
Identifiers
42560537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.